Related Experiment Video
Updated: Aug 19, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Antiviral activity of nirmatrelvir against contemporary SARS-CoV-2 variants
Irina Yurgelonis1, Devendra K Rai2, Jonathan T Lee3
1Anti-Infectives, Pfizer Inc, Pearl River, NY, 10965, USA.
Abstract:
Nirmatrelvir, the active antiviral component of Paxlovid®, was evaluated for potency against 20 genetically diverse and clinically relevant SARS-CoV-2 variants circulating between 2020 and 2024. Robust in vitro antiviral activity was demonstrated against all tested variants, with only modest reductions in susceptibility observed for certain Beta variants. SARS-CoV-2 main protease (Mpro), the target of nirmatrelvir, is conserved among contemporary variants JN.1, XEC, KP.3.1.1, NB.1.8.1, LP.8.1, XFG, and BA.3.2, based on amino acid sequence identity. The key binding residues for nirmatrelvir in Mpro remain highly conserved, supporting its continued effectiveness in the treatment of mild-to-moderate COVID-19. These findings demonstrate that nirmatrelvir maintains antiviral activity across multiple SARS-CoV-2 variants.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Respiratory Syncytial Virus Disease
Subviral Agents

